Adaptate

A spin-off of GammaDelta Therapeutics in London, Adaptate was developing new treatments for cancer, both haematological and solid tumors, using novel antibody-based γδ T cell engagers designed to specifically modulate γδ T cell-mediated immune responses at tumor sites while sparing damage to healthy cells. Takeda, which had previously acquired GammaDelta Therapeutics and its γδ T cell-based therapies, also had an option to acquire Adaptate, and it did so in 2022.